Study demonstrates potential for the Guardant360 Assay to predict which patients will benefit from Immunotherapy – DOTmed.com
|
Study demonstrates potential for the Guardant360 Assay to predict which patients will benefit from Immunotherapy
DOTmed.com REDWOOD CITY, Calif., Oct. 2, 2017 /PRNewswire/ — Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent research suggests. In a paper published in Clinical … |
